Biotech 2009 to Feature Global Industry Leaders and Cover the Latest Topics and Trends Relevant to the Bioscience Industry
TRENTON, N.J. & MALVERN, Pa.–(BUSINESS WIRE)–Biotech 2009 (www.biotech2009.org) will bring together globally-recognized industry leaders to address key trends and topics relevant to the growth and advancement of the tri-state region’s bioscience industry.
Throughout the two-day event, more than 100 speakers, including 44 C-level executives, will discuss topics on key financial, scientific, business, and regulatory issues that are impacting the bioscience industry. This industry is integral to the economy of the tri-state region and the sessions at Biotech 2009 will address the key trends that have, and will continue, to affect the bioscience industry in this region.
Highlighted by keynotes from David Holveck, president & CEO of Endo Pharmaceuticals and Fred Hassan, chairman and CEO of Schering-Plough, Biotech 2009 will provide many interview opportunities for reporters who cover a variety of topics including business, finance, health, and science. This annual bioscience symposium is the largest such conference held in the region. Complimentary registration is available for credentialed members of the news media by e-mailing info@biotech2009.org.
For business and finance reporters:
- 44 C-level executives will speak at the conference including 27 CEOs, 7 CFOs, 7 CSOs, 1 CLO, 1 CCO, and 1 CTO.
- Keynote speakers:
- David Holveck, president & CEO of Endo Pharmaceuticals, will focus on the challenge of balancing growth and innovation in the rapidly evolving health care landscape (November 16 dinner).
- Fred Hassan, chairman & CEO of Schering-Plough will engage in an intimate “fireside chat” on the theme “Leadership in a Time of Change: The Next 10 Years in Biotech” (November 17 lunch).
- A plenary session focused on the past, present, and future state of the biotechnology industry on November 16.
- Company presentations on November 16 featuring a diverse group of 37 bioscience companies from throughout the Mid-Atlantic region and beyond.
- A Growth Strategies track on November 16 with sessions on the virtual business model, creative partnering, and developing value for your exit strategy.
- A Regulatory track on November 16 with sessions on biosimilars, the FDA Amendments Act, and FDA/industry interactions while preparing for a pandemic.
- A Finance track on November 17 with topics such as navigating the capital markets, cash preservation strategies, and creative financing transactions.
- A Hot Topics in Business track on November 17 featuring sessions on the redefined role of venture capitalists, impact of health care reform, and building value in a development-stage company.
For health and science reporters:
- A Drug Delivery, Device, and Diagnostics track on November 16 with sessions on the role of diagnostics in bioscience technology and health care, new trends in drug delivery, and advancements for the diagnosis and treatment of neurological disorders.
- A Hot Topics in Science track on November 17 with topics on immunotherapeutics, regenerative medicine, and mitochondrial targets.
- An Innovation Corridor featuring more than 50 scientific posters from some of the region’s most innovative young companies and research institutions.
C-level executives speaking at the symposium include:
- William “Chip” Baird, CFO, PTC Therapeutics, Inc.
- Ronald Berg, CEO, RadPharm, Inc.
- Bruce Bloom, DDS, J.D., president and CSO, Partnership for Cures
- Tauseef Butt, Ph.D., president and CEO, LifeSensors, Inc.
- Geert Cauwenbergh, Ph.D., chairman & CEO, RHEI Pharmaceuticals and founder & CEO, Phases123
- Rodney Dausch, vice president of project management & CFO, Morphotek, Inc.
- Manya Deehr, chief legal officer and corporate secretary, Eurand
- James Dentzer, CFO, Amicus Therapeutics
- Michael Detke, M.D., Ph.D., chief medical officer, MedAvante & director, MedAvante Research Institute, clinical associate professor of psychiatry, Indiana University School of Medicine, and research affiliate, McLean Hospital & Research Associate, Harvard Medical School
- Andy Drechsler, CFO, VaxInnate
- John Fraher, chief commercial officer, Eurand
- Doug Gessl, CFO, Ception Therapeutics, Inc.
- Paul Gilbert, CEO, MedAvante, Inc.
- John Gill, president, CEO, director & founder, TetraLogic Pharmaceuticals
- Keith Goldan, CPA, MBA, vice president & CFO, NuPathe Inc.
- Ulrich Grau, Ph.D., president and CEO, Lux Biosciences, Inc.
- Valentin Gribkoff, Ph.D., CSO & senior vice president, discovery research, Knopp Neurosciences, Inc.
- Kevin Harter, executive chairman, Saladax Biomedical, Inc.
- Fred Hassan, chairman & CEO, Schering-Plough Corporation
- Thomas Hess, CPA, senior vice president, finance and CFO, Yaupon Therapeutics Inc.
- Jane Hollingsworth, CEO, NuPathe Inc.
- David Holveck, president & CEO, Endo Pharmaceuticals
- Mark Leahey, president & CEO, Medical Device Manufacturers Association
- Brian Leuthner, president & CEO, Edge Therapeutics, Inc.
- Maria Maccecchini, Ph.D., president & CEO, QR Pharma, Inc.
- R. Loch Macdonald, M.D., Ph.D., co-founder and CSO, Edge Therapeutics, Inc.
- John Maki, president & CEO, Vicus Therapeutics
- Vincent Milano, president and CEO, ViroPharma Incorporated
- Francois Nader, M.D., president & CEO, NPS Pharmaceuticals, Inc.
- Bob Pearson, chief technology & media officer, WeissComm Group
- Stuart Peltz, Ph.D., president & CEO, PTC Therapeutics Inc.
- H. Joseph Reiser, Ph.D., president & CEO, CureDM Inc.
- James Sapirstein, R.Ph., MBA, president & CEO, Tobira Therapeutics, Inc.
- Barbara Schilberg, managing director & CEO, BioAdvance
- J. Howison Schroeder, president and CEO, Neuro Kinetics, Inc.
- Marvin Schwalb, Ph.D., vice president & CSO, CGC Genetics, Inc.
- Neal Simon, Ph.D., CEO, Azevan Pharmaceuticals, Inc.
- Daniel Skovronsky, M.D., Ph.D., CEO, Avid Radiopharmaceuticals, Inc.
- Gary Slatko, M.D., MBA, chief medical officer, ParagonRx, LLC
- Jack Stover, executive chairman, Targeted Nano Therapeutics
- Stephen Tang, Ph.D., president & CEO, University City Science Center
- Paul Touhey, president & CEO, Fujirebio Diagnostics, Inc.
- Raymond Vennare, co-founder & CEO, ThermalTherapeutic Systems, Inc.
- Clarence Young, M.D., vice president, drug development & chief medical officer, Protez Pharmaceuticals, Inc.
About Biotech 2009
Biotech 2009: Imagine. Collaborate. Innovate is designed to advance the growth and development of the bioscience industry in the Mid-Atlantic region. In its ninth year, this event is a joint symposium of BioNJ and Pennsylvania Bio. For more information, please visit www.biotech2009.org.
